Capricor Therapeutics (CAPR) Research & Development (2010 - 2026)

Capricor Therapeutics' Research & Development history runs 17 years deep, the most recent figure standing at $27.4 million for Q1 2026.

• On a quarterly basis, Research & Development rose 44.73% year-over-year to $27.4 million in Q1 2026; TTM through Mar 2026 was $92.9 million, a 60.72% increase from a year earlier, with the FY2025 full-year figure at $84.5 million, up 69.02% from the prior year.
• Research & Development climbed to $27.4 million in Q1 2026 per CAPR's latest filing, from $23.2 million in the prior quarter.
• Across five years, Research & Development topped out at $27.4 million in Q1 2026 and bottomed at $5.0 million in Q2 2022.
• The 5-year median for Research & Development is $11.1 million (2024), against an average of $12.9 million.
• Across the five-year window, Research & Development soared 120.17% in 2022 and rose 17.74% in 2024, its largest moves.
• Year by year, Research & Development stood at $6.2 million in 2022, then soared by 60.45% to $9.9 million in 2023, then jumped by 46.45% to $14.6 million in 2024, then jumped by 58.94% to $23.2 million in 2025, then advanced by 18.24% to $27.4 million in 2026.
• Per Business Quant, the three latest CAPR Research & Development figures stand at $27.4 million (Q1 2026), $23.2 million (Q4 2025), and $20.4 million (Q3 2025).